Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-authorization Safety Study to Prospectively Monitor the Incidence of Relevant Drug-related Adverse Events and EPO-related Lack of Efficacy Among CKD Subjects Receiving HX575 Recombinant Human Erythropoietin Alfa i.v.

NCT00632125 is registered in ClinicalTrials.gov with Sandoz as lead sponsor.

NCT NCT00632125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00632125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-authorization Safety Study to Prospectively Monitor the Incidence of Relevant Drug-related Adverse Events and EPO-related Lack of Efficacy Among CKD Subjects Receiving HX575 Recombinant Human Erythropoietin Alfa i.v.
Lead sponsor
Sandoz
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2008
Completion date
September 30, 2010
Enrollment
1,695 (actual)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease